Longevity intelligence, from science to markets: what happened, why it matters, and what it means for the companies around it.
Biogen's Phase 2 CELIA trial of diranersen in early Alzheimer's disease demonstrated cognitive benefits and robust tau pathology reduction at 18 months, supporting plans for Phase 3 development despite missing its primary dose-response endpoint.
ReadFrom the published articles above. Relationship mapping only — not market data.
Development preview only — not published LONGEFI News.
New England Journal of Medicine · 7 Aug 2026
Two-year follow-up from an in vivo CRISPR programme shows sustained protein knockdown after a single infusion, with no late safety signals reported. Durability at this length strengthens the case that one-time editing can replace chronic therapy. The result is indication-specific but platform-relevant.
In vivo CRISPR · LNP delivery
What LONGEFI selected from the illustrative preview stream.
The workshop reviewed evidence for methylation clocks as surrogate endpoints across 14 candidate trials.
Without an accepted surrogate endpoint, longevity trials must measure disease or function, which takes years and large samples.
146 patients with diabetic macular edema received either the senolytic candidate or standard anti-VEGF therapy.
Senolytics have struggled with systemic tolerability. Local delivery sidesteps that problem and gives the mechanism its first credible human durability data.
The team used a doxycycline-controlled system to express three reprogramming factors (Oct4, Sox2, Klf4) in two-day pulses across a nine-month protocol in 22-month-old mice.
Most reprogramming results to date have reported changes in molecular markers. This study reports changes in function — how well the animal actually repairs itself — which is the endpoint that eventually matters clinically.
Researchers linked midlife metabolic panels to epigenetic age estimates collected 18-24 years later.
Metabolic dysfunction is measurable cheaply and early, making it the most practical target for population-scale longevity intervention.
Companies referenced by the illustrative preview developments only — never by live News.
